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Sir,
Huhtinen et al (2009) recently reported about the usefulness
of Human Epididymal Protein 4 (HE4) in discriminating
ovarian tumours from ovarian endometriotic cysts, which is of
pivotal importance as CA125 is often increased in benign
gynaecological diseases such as endometriosis (Muyldermans
et al, 1995). Therefore, we performed a similar study on 46
patients affected by ovarian cancer and 21 patients affected by
endometriosis (12 ovarian endometrioma and 9 non-ovaric
endometriosis). Serum levels of CA125 were determined using a
chemiluminescent enzyme immunoassay on the Liaison (DiaSorin,
Saluggia, Italy). Serum levels of HE4 were determined using
an ELISA kit developed by Fujirebio Diagnostic Inc. (Malvern, PA,
USA).
The mean serum concentration of HE4 in patients with ovarian
cancer was significantly higher than that observed in patients with
endometriosis (810.0 vs 49.4pM, Po0.0001). The mean serum
concentrations of HE4 in our patients with ovarian endometrioma
were similar to those observed in the study of Huhtinen et al
(2009) (47.5 vs 46.0pM). However, in our investigation, 10 out of 12
patients with ovarian endometrioma showed CA125 values higher
than 35Uml
1, but only one patient showed an HE4 serum
concentration higher than 70pM, which is the upper limit of the
reference range (Moore et al, 2008). More importantly, receiver
operator characteristic curve analysis showed that HE4 has a
significantly higher area under the curve as compared with CA125
(0.85 vs 0.77, Po0.0001) for differentiating ovarian cancer from
ovarian endometrioma. The results of our investigation confirm
that HE4 is a promising marker for the early differentiation of
ovarian cancer from ovarian endometriotic cysts, showing better
diagnostic performances than CA125.
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